3l29
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | {{Seed}} | ||
| - | [[Image:3l29.png|left|200px]] | ||
| - | |||
| - | <!-- | ||
| - | The line below this paragraph, containing "STRUCTURE_3l29", creates the "Structure Box" on the page. | ||
| - | You may change the PDB parameter (which sets the PDB file loaded into the applet) | ||
| - | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | ||
| - | or leave the SCENE parameter empty for the default display. | ||
| - | --> | ||
{{STRUCTURE_3l29| PDB=3l29 | SCENE= }} | {{STRUCTURE_3l29| PDB=3l29 | SCENE= }} | ||
| - | |||
===Crystal Structure of Zaire Ebola VP35 interferon inhibitory domain K319A/R322A mutant=== | ===Crystal Structure of Zaire Ebola VP35 interferon inhibitory domain K319A/R322A mutant=== | ||
| + | {{ABSTRACT_PUBMED_20071589}} | ||
| - | + | ==Function== | |
| - | + | [[http://www.uniprot.org/uniprot/VP35_EBOZM VP35_EBOZM]] Acsts as a polymerase cofactor in the RNA polymerase transcription and replication complex. Prevents establishment of cellular antiviral state by blocking virus-induced phosphorylation and activation of interferon regulatory factor 3 (IRF3), a transcription factor critical for the induction of interferons alpha and beta. The mechanism by which this blockage occurs remains incompletely defined, a hypothesis suggests that VP35 dsRNA-binding activity prevents activation of IRF3 by sequestering dsRNA. Also inhibits the antiviral effect mediated by the interferon-induced, double-stranded RNA-activated protein kinase EIF2AK2/PKR.<ref>PMID:9971816</ref> <ref>PMID:11027311</ref> <ref>PMID:12829834</ref> <ref>PMID:16495261</ref> <ref>PMID:17065211</ref> | |
| - | + | ||
| - | + | ||
| - | --> | + | |
| - | + | ||
==About this Structure== | ==About this Structure== | ||
| - | + | [[3l29]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Zaire_ebolavirus Zaire ebolavirus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3L29 OCA]. | |
==Reference== | ==Reference== | ||
| - | <ref group="xtra">PMID: | + | <ref group="xtra">PMID:020071589</ref><references group="xtra"/><references/> |
[[Category: Zaire ebolavirus]] | [[Category: Zaire ebolavirus]] | ||
[[Category: Amarasinghe, G K.]] | [[Category: Amarasinghe, G K.]] | ||
| Line 29: | Line 16: | ||
[[Category: Leung, D W.]] | [[Category: Leung, D W.]] | ||
[[Category: Ramanan, P.]] | [[Category: Ramanan, P.]] | ||
| - | [[Category: Coiled coil]] | ||
[[Category: Host cytoplasm]] | [[Category: Host cytoplasm]] | ||
[[Category: Interferon antiviral evasion]] | [[Category: Interferon antiviral evasion]] | ||
| Line 39: | Line 25: | ||
[[Category: Transcription]] | [[Category: Transcription]] | ||
[[Category: Virion]] | [[Category: Virion]] | ||
| - | |||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Mar 31 12:27:35 2010'' | ||
Revision as of 20:40, 4 April 2013
Contents |
Crystal Structure of Zaire Ebola VP35 interferon inhibitory domain K319A/R322A mutant
Template:ABSTRACT PUBMED 20071589
Function
[VP35_EBOZM] Acsts as a polymerase cofactor in the RNA polymerase transcription and replication complex. Prevents establishment of cellular antiviral state by blocking virus-induced phosphorylation and activation of interferon regulatory factor 3 (IRF3), a transcription factor critical for the induction of interferons alpha and beta. The mechanism by which this blockage occurs remains incompletely defined, a hypothesis suggests that VP35 dsRNA-binding activity prevents activation of IRF3 by sequestering dsRNA. Also inhibits the antiviral effect mediated by the interferon-induced, double-stranded RNA-activated protein kinase EIF2AK2/PKR.[1] [2] [3] [4] [5]
About this Structure
3l29 is a 2 chain structure with sequence from Zaire ebolavirus. Full crystallographic information is available from OCA.
Reference
- Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP, Ramanan P, Cardenas WB, Amarasinghe GK, Volchkov VE, Basler CF. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol. 2010 Mar;84(6):3004-15. Epub 2010 Jan 13. PMID:20071589 doi:10.1128/JVI.02459-09
- ↑ Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol. 1999 Mar;73(3):2333-42. PMID:9971816
- ↑ Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, Garcia-Sastre A, Palese P. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94. PMID:11027311 doi:10.1073/pnas.220398297
- ↑ Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, Klenk HD, Palese P, Garcia-Sastre A. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol. 2003 Jul;77(14):7945-56. PMID:12829834
- ↑ Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, Kroeker AD, Iversen PL, Bavari S, Muhlberger E. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother. 2006 Mar;50(3):984-93. PMID:16495261 doi:10.1128/AAC.50.3.984-993.2006
- ↑ Feng Z, Cerveny M, Yan Z, He B. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol. 2007 Jan;81(1):182-92. Epub 2006 Oct 25. PMID:17065211 doi:JVI.01006-06
